# Sebastiano Buti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sebastiano-buti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,908 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 46 |
| i10-index | 185 |
| Last Known Institution | University of Parma |
| OpenAlex ID | https://openalex.org/A5013913173 |
| ORCID iD | 0000-0003-0876-0226 |
| Works | 663 |

## Researcher papers

- [A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable](https://scholariq.org/papers/a-multicenter-study-of-body-mass-index-in-cancer-patients-treated-with-anti-pd-1/)
- [Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab](https://scholariq.org/papers/association-of-systemic-inflammation-index-and-body-mass-index-with-survival-in/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/)
- [Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients](https://scholariq.org/papers/correlations-between-the-immune-related-adverse-events-spectrum-and-efficacy-of/)
- [Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer](https://scholariq.org/papers/clinical-outcomes-and-toxic-effects-of-single-agent-immune-checkpoint-inhibitors/)
- [Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program](https://scholariq.org/papers/real-world-efficacy-and-safety-of-nivolumab-in-previously-treated-metastatic/)
- [The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC](https://scholariq.org/papers/the-circulating-pool-of-functionally-competent-nk-and-cd8-cells-predicts-the/)
- [Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events](https://scholariq.org/papers/another-side-of-the-association-between-body-mass-index-bmi-and-clinical/)
- [Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients](https://scholariq.org/papers/soluble-pd-l1-and-circulating-cd8-pd-1-and-nk-cells-enclose-a-prognostic-and/)
- [From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC](https://scholariq.org/papers/from-the-beginning-to-resistance-study-of-plasma-monitoring-and-resistance/)
- [Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies](https://scholariq.org/papers/resistance-to-osimertinib-in-advanced-egfr-mutated-nsclc-a-prospective-study-of/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [University of Parma](https://scholariq.org/institutions/university-of-parma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.